IgGenix Presents Data Supporting Clinical Development of IGNX001 for Peanut Allergy at the 2024 ASCIA Annual Conference ...Middle East

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented exciting data on the company's lead candidate, IGNX001, an IgG4 monoclonal...

Hence then, the article about iggenix presents data supporting clinical development of ignx001 for peanut allergy at the 2024 ascia annual conference was published today ( Tuesday 03/09/2024 - 02:13 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IgGenix Presents Data Supporting Clinical Development of IGNX001 for Peanut Allergy at the 2024 ASCIA Annual Conference )

Also on site :

• One dead, four wounded in downtown Oakland bar shooting
• Lebanese army: Three soldiers, several civilians martyred in bombing accompanying Israeli landing operation in Baalbek
• Democrat Shutdowns Threaten Homeland Security Amid Heightened Threats .. Opinion